For \>100 years, large, seasonal epidemics of meningococcal meningitis have occurred periodically in the African meningitis belt \[[@JIV211C1]\], causing thousands of cases and many deaths and severely disrupting health systems \[[@JIV211C2]\]. Meningitis and septicemia are rare outcomes of meningococcal infection, and most infections with *Neisseria meningitidis* result in asymptomatic pharyngeal carriage. Therefore, the underlying transmission dynamics can be determined accurately only by study of carriage and disease, a feature of *N. meningitidis* infection first recognized 70 years ago \[[@JIV211C3]\].

In high-income countries, meningococcal carriage occurs most frequently in older children and young adults and is linked to smoking, nightclub attendance, and intimate kissing \[[@JIV211C4]\]. Less is known about the epidemiology and risks factors of meningococcal carriage in the African meningitis belt. A review of studies undertaken in the meningitis belt prior to 2007 showed that the prevalence of meningococcal carriage varied markedly between surveys, as did the distribution of serogroups \[[@JIV211C5]\]. Some of these differences may have arisen because surveys were undertaken at different times of the year and in different age groups and because they used a variety of swabbing and microbiological techniques. Only a few additional African carriage studies have been reported since the 2007 review, all from Burkina Faso, and these have also shown considerable heterogeneity \[[@JIV211C6]--[@JIV211C10]\]. In 2009, Kristiansen et al conducted large, sequential carriage studies in participants aged 1--29 years in 1 urban and 2 rural communities in Burkina Faso \[[@JIV211C9]\] prior to introduction of a new serogroup A meningococcal polysaccharide/tetanus toxoid conjugate vaccine (PsA-TT; MenAfriVac). The prevalence of carriage among 20 326 participants was 4.0%, with the highest prevalence among males aged 15--19 years and females aged 10--14 years.

Because carriage is central to an understanding of the epidemiology of meningococcal infection in the African meningitis belt, the African Meningococcal Carriage Consortium (MenAfriCar) was established in 2008 to study the pattern of meningococcal carriage in this region before and after the introduction of PsA-TT, using standardized field and laboratory methods \[[@JIV211C11]\]. Here we report the findings from 20 age-stratified, cross-sectional surveys conducted in 7 countries before and in 3 countries after the introduction of PsA-TT.

METHODS {#s2}
=======

The field and laboratory methods used in the MenAfriCar surveys have been described in detail previously \[[@JIV211C11]\] and are summarized here.

Study Sites and Carriage Surveys {#s2a}
--------------------------------

Carriage studies were conducted in 1 urban and 1 rural area in 7 countries in the meningitis belt ([Supplementary Figure 1](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1)) during the dry seasons of 2010 and 2011 and during the rainy season of 2012. Following pilot studies \[[@JIV211C12]\], 3 cross-sectional surveys were undertaken in all countries except Nigeria, where only 2 surveys could be done because of increasing political instability. Prevaccination surveys in Mali, Niger, and Chad had a target of 5000 participants, and postvaccination surveys a target of 2000 participants in Mali and Niger and 6000 in Chad. The remaining surveys had a target of 2000 participants. A representative sample frame was obtained either from an updated, ongoing demographic surveillance system (DSS) or from a census conducted specifically for the study. Multistage sampling was used. Study households were randomly selected from the DSS or census. Within selected households, individuals stratified by age group (0--4 years, 5--14 years, 15--29 years, and ≥30 years) were chosen randomly until the required sample size was reached. Following receipt of written consent, standardized household and individual questionnaires enquiring about risk factors for meningococcal infection were administered.

Based on an estimated serogroup A meningococcal carriage rate of 1% in prevaccination surveys, a sample size of 2000 was estimated to be large enough to enable meaningful comparisons to be made between countries, site (urban vs rural), season, and age group. A sample of 5000 was estimated to have 80% power to show a 50% reduction in serogroup A carriage following vaccination.

Isolation and Characterization of Meningococci {#s2b}
----------------------------------------------

### Swabbing Technique {#s2b1}

Pilot studies established that swabbing both the posterior pharynx and the tonsils or just the posterior of the pharynx were equally effective methods of isolating *N. meningitidis* \[[@JIV211C12]\], and the former method was used in all subsequent surveys.

### Identification of *N. meningitidis* {#s2b2}

Pharyngeal swabs were plated directly onto modified Thayer-Martin agar plates in the field and taken to the laboratory within 6 hours of collection. Details of the conventional bacteriological techniques used to identify and serogroup meningococci \[[@JIV211C11]\] are provided in the [Supplementary Materials](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1). At 6 of 7 African centers, *porA* polymerase chain reaction (PCR) was undertaken to confirm the identity of isolates of *N. meningitidis* identified by routine microbiological analysis, and if this test had positive results, an A, X, and W multiplex genogrouping PCR was performed. If the result of this first multiplex PCR was negative, singleplex Y genogrouping PCR was performed.

To confirm the identity of *Neisseria* identified by culture, samples of boiled suspensions of oxidase-positive, gram-negative bacteria were sent to the University of Oxford for molecular analysis \[[@JIV211C11], [@JIV211C13]\], as described in the [Supplementary Materials](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1). Speciation was done by sequencing the ribosomal protein L6 gene *rplF* \[[@JIV211C13]\], and *N. meningitidis* isolates were characterized by sequencing the 2 variable regions of the *porA* gene and of the capsule-null (*cnl)* intergenic region to identify unencapsulated bacteria. Finally, genogroups were identified by using 2 multiplex real-time PCR assays to detect genes encoding capsules corresponding to the disease-associated serogroups A, B, C, W, X, and Y (giving the respective genogroup).

Data Management {#s2c}
---------------

Data were managed using the Teleform system as described previously \[[@JIV211C11]\]. This allows study forms to be specifically designed, scanned after completion, automatically read, and then verified before being exported to a database. Local and central databases were designed to accommodate the study forms, and a separate database module was developed to automatically populate the central database with genetic laboratory results from the *Neisseria* sequence typing database (<http://PubMLST.org/Neisseria>) \[[@JIV211C14], [@JIV211C15]\]. Records from laboratory reports and questionnaires were linked using the unique study number assigned to each individual. Data cleaning was performed using Stata, version 12.0 (StataCorp, College Station, Texas). Any laboratory report that could not be linked to a questionnaire that contained information on the age of the participant was excluded. These exclusions are shown in [Supplementary Table 1](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1); only 18 meningococci, 15 of which were from the first survey, were excluded.

Statistical Methods {#s2d}
-------------------

Analyses were performed using Stata, version 12.0. We accounted for potential household clustering, using the survey commands in Stata. Overall and age-stratified carriage prevalence rates were calculated, together with 95% confidence intervals (CIs), for each country and each survey. The Simpson diversity index was calculated for each country, based on the strains (genogroup and PorA subtype) isolated across all surveys. Risk factors for carriage were assessed using logistic regression. Each risk factor was considered in turn, using univariable logistic regression. A multivariable model was then constructed that included country, season, age group, and sex a priori and any variable with a *P* value of \<.1 in the univariable analyses, with those with a *P* value of \<.05 in the multivariable analysis retained. As a final check, dropped variables were reentered into the model one at a time, and the *P* values were reexamined; the variable was retained if *P* \< .05. A multinomial logistic regression model was constructed to compare risk factors for carriage of meningococci with and those without capsular genes.

RESULTS {#s3}
=======

Participants Surveyed {#s3a}
---------------------

The number of participants in each survey, the year and season of the survey, and the relationship of the survey to the introduction of PsA-TT are shown in Table [1](#JIV211TB1){ref-type="table"}. Most surveys recruited close to their target number of participants, and there was even sampling between age groups ([Supplementary Table 2](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1)). Participants aged 5--29 years were recruited preferentially for the postvaccination survey in Chad in 2012 to maximize the chance of identifying serogroup A meningococcal carriers and of being able to assess the impact of vaccination. Table 1.Numbers of Subjects Studied, by Country, During Each SurveyCountrySurvey 1, Rainy Season, July--December 2010Survey 2, Rainy Season, July--November 2011Survey 3, Dry Season, February--July 2012Chad198653076103^a^Ethiopia188420252061Ghana115920312019Mali48441994^a^1999^a^Niger42351963^a^2015^a^Nigeria15209360Senegal141416801315 Overall17 04215 93615 512[^2]

Prevalence of *N. meningitidis* Carriage {#s3b}
----------------------------------------

A total of 1687 meningococci were identified, for an overall carriage prevalence of 3.4% (95% CI, 3.2%--3.6%) after adjustment for survey design. There was marked variation in the prevalence of carriage between centers and between surveys within each center (Figure [1](#JIV211F1){ref-type="fig"}). The age distribution of carriers by center and survey was more consistent (Figure [2](#JIV211F2){ref-type="fig"}). Combining the results from all surveys, the prevalence of carriage by age was 1.8% (95% CI, 1.3%--2.4%) for \<1 year, 2.6% (95% CI, 2.2%--2.9%) for 1--4 years, 4.9% (95% CI, 4.5%--5.3%) for 5--14 years, 3.6% (95% CI, 3.2%--3.9%) for 15--29 years, and 2.6% (95% CI, 2.3%--2.9%) for ≥30 years. The age distribution of carriers by country and survey is shown in [Supplementary Figure 2](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1). The overall prevalence of carriage in males (4.1%; 95% CI, 3.8%--4.3%) was higher than in females (3.0%; 95% CI, 2.7%--3.2%), and this difference was seen in 5 of 7 participating countries. The most marked sex difference in prevalence was seen in 15--29 year olds, in whom carriage in males was significantly higher than in females (5.1% vs 2.8%; *P* \< .0001; Figure [3](#JIV211F3){ref-type="fig"}). Generally, the prevalence of carriage was higher in the dry season (4.2%; 95% CI, 3.8%--4.5%) than in the rainy season (3.1%; 95% CI, 2.9%--3.3%); this difference was observed in 4 of 7 participating countries. The prevalence of carriage was higher in rural areas (3.6%; 95% CI, 3.3%--3.9%) than in urban areas (3.2%; 95% CI, 2.9%--3.5%), and this difference, although not statistically significant, was observed in 5 of 7 participating countries ([Supplementary Table 3](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1)). The most frequently identified *Neisseria* species other than *N. meningitidis* was *Neisseria lactamica* (2588 individuals \[5.4%\]); other *Neisseria* species were found at a lower prevalence. Figure 1.Carriage prevalence, by country and survey. Asterisks denote postvaccination surveys. Figure 2.Carriage prevalence, by age and survey. Figure 3.Carriage prevalence, by age and sex (all surveys combined).

Strain Characteristics of *N. meningitidis* Carriage Isolates {#s3c}
-------------------------------------------------------------

Genes characteristic of disease-associated capsules were detected in 48% of the 1687 meningococci identified: genogroup A, 46 isolates (0.09% overall prevalence); genogroup B, 17 isolates (0.04%); genogroup C, 30 isolates (0.06%); genogroup W, 623 isolates (1.3%); genogroup X, 27 isolates (0.06%); and genogroup Y, 68 isolates (0.14%). Two genogroups were identified in 3 samples: 2 with genogroup A and X, and 1 with genogroup X and C. The overall prevalence of carriage with *cnl* meningococci was 1.6% (778 isolates). Neither a capsular gene nor the *cnl* intergenic region was detected in 101 samples identified microbiologically as *N. meningitidis.* It is likely that these were meningococci with capsules not usually associated with disease and whose capsular genes were not detected \[[@JIV211C16]\]. In 169 samples identified as meningococci, we found evidence of both a capsule-null locus and a capsular gene. This suggests that there was cocolonization with \>1 meningococcal strain or perhaps cocolonization with 2 different *Neisseria* species, as the *cnl* intergenic region is present in all nonmeningococcal *Neisseria* species, as well as some meningococci. The distribution of the different genogroups varied substantially by center and survey (Figure [4](#JIV211F4){ref-type="fig"}*A*--*C*). Although numbers within subgroups were small, there was no indication that that genogroup was associated preferentially with a particular age group or sex within the context of a country or survey ([Supplementary Table 4](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1)). Figure 4.Distribution of *Neisseria meningitidis* genogroups, by country and survey. The overall prevalence of carriage in each country during the survey is shown in brackets. *A*, First cross-sectional survey in 2010 (rainy season). At this time, no country had introduced serogroup A meningococcal conjugate vaccine (MenAfriVac). *B*, Second cross-sectional survey in 2011 (rainy season). At this time, MenAfriVac had been introduced in Mali and Niger, as indicated by asterisks. *C*, Third cross-sectional survey in 2012 (dry season). At this time, MenAfriVac had been introduced in Mali, Niger, and Chad, as indicated by asterisks.

A wide diversity of porA subtypes was recorded, with 63 unique combinations identified among the samples typed for both VR1 and VR2. However, 3 subtypes accounted for 68.8% of all the meningococci isolated. The most frequently detected subtype was P1.18-11,42-1 (n = 547), which was usually associated with the presence of the *cnl* intergenic region (93%). The next most common subtype was P1.5,2 (n = 493), which was strongly associated with genogroup W (97%), followed by P1.5-1,2--36 (n = 121), which was also associated strongly with genogroup W (89%). Forty-one of the 46 genogroup A meningococci were subtyped as P1.20,9.

The combination of genogroup and PorA subtype provides a strain designation; 132 distinct strains were identified. The most frequently identified strain type was NG(*cnl*):P1.18-11,42-1 (n = 511), followed by W:P1.5,2 (n = 479) and W:P1.5-1,2-36 (n = 108). All other strain types were isolated on \<50 occasions. The strain distribution by country and by survey is illustrated in Figure [5](#JIV211F5){ref-type="fig"}. More strain diversity was observed in Ethiopia and Senegal, countries at the eastern and western edges of the meningitis belt, than in countries situated in the central part of the belt. The Simpson diversity index (from most to least diverse) was estimated to be 0.021 in Ethiopia, 0.031 in Senegal, 0.035 in Niger, 0.051 in Ghana, 0.052 in Chad, and 0.073 in Mali. Meningococci isolated in Ethiopia were \>3 times as diverse as those from Mali. Figure 5.Distribution of strain types across the meningitis belt. The number of meningococci isolated in each country is indicated. *A*, Survey 1 (2010). At this time, no country had introduced serogroup A meningococcal conjugate vaccine (MenAfriVac). *B*, Survey 2 (2011). At this time, MenAfriVac had been introduced in Mali and Niger, as indicated by asterisks. *C*, Survey 3 (2012). At this time, MenAfriVac had been introduced in Mali, Niger, and Chad, as indicated by asterisks.

Risk Factors for *N. meningitidis* Carriage {#s3d}
-------------------------------------------

Risk factors for carriage with *N. meningitidis* at the individual level are shown in Table [2](#JIV211TB2){ref-type="table"}. Age, sex, season, rural site, crowding (≥2 people per room), smoking in the household, and indoor kitchen facilities remained statistically significant risk factors in a multivariable logistic regression analysis. Recent immunization (within 1 year) with a meningitis vaccine (self-reported) was associated with a lower odds of carriage of capsulated meningococci, after accounting for other factors. Respiratory symptoms and a history of attending social gatherings in the past week were associated with a lower odds of carriage in univariable analysis, but both variables dropped out in multivariable analysis. Risk factors for carriage of genogroupable and capsule-null meningococci are shown in [Supplementary Table 5](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiv211/-/DC1). Dry season and the location of the kitchen were associated significantly with a higher odds of carriage of genogroupable but not *cnl* meningococci. Table 2.Univariable and Multivariable Logistic Regression Analysis of Factors Associated With *Neisseria meningitidis* CarriageFactorSubjects, No. (Carriers, No.)Crude OR (95% CI)Adjusted OR (95% CI)Age, y \<12199 (41)0.50 (.37--.69)0.37 (.27--.51) 1--48839 (228)0.72 (.61--.84)0.59 (.50--.69) 5--1413 121 (655)1.41 (1.35--1.58)1.41 (1.25--1.60) 15--2912 426 (450)1.01.0 ≥3011 905 (313)0.72 (.62--.83)0.60 (.51--.69)Sex^a^ Female27 981 (835)1.01.0 Male20 353 (825)1.37 (1.25--1.51)1.17 (1.10--1.24)Season Rainy (XS1 and XS2)32 978 (1039)1.01.0 Dry (XS3)15 512 (648)1.31 (1.21--1.53)1.54 (1.37--1.75)Country Chad13 396 (131)1.01.0 Ethiopia5970 (389)7.12 (5.71--8.89)7.04 (5.39--9.21) Ghana5209 (193)4.03 (3.15--5.15)4.76 (3.62--6.29) Mali8837 (79)0.95 (.71--1.27)1.42 (1.03--195) Niger8213 (535)7.27 (5.93--8.93)10.16 (8.03--12.84) Nigeria2456 (3)0.09 (.02--.35)0.11 (.03--.45) Senegal4409 (357)9.23 (7.40--11.50)9.58(7.30--12.58)Area Urban20 218 (644)1.01.0 Rural28 205 (1017)1.14 (1.01--1.28)1.44 (1.28--1.63)Crowding^b^ \<2 people per room16 908 (460)1.01.0 ≥2 people per room31 515 (1201)1.42 (1.25--1.61)1.24 (1.09--1.42)Smoking status^c^ Nonsmoker22 312 (705)1.0... Smoker1231 (43)1.11 (.81--1.51)...Smokers in household No35 523 (1164)1.01.0 Yes12 881 (497)1.18 (1.04--1.34)1.16 (1.02--1.33)Cooking fuel Oil based533 (7)0.46 (.22--.97)... Wood based41 825 (11721.0... Cow dung/straw5729 (472)3.11 (2.73--3.55)...Kitchen location Open air18 934 (512)1.01.0 Inside house13 322 (824)2.37 (2.09--2.70)1.35 (1.12--1.63) Separate hut15 268 (304)0.72 (.61--.84)0.95 (.77--1.18) Missing information595 (21)1.32 (.73--2.38)1.11 (.60--2.07)Vaccinated recently with meningitis vaccine No33 598 (1230)1.01.0 Yes, \<1 y ago9132 (227)0.67 (.57--.78)0.72 (.60--.85) Yes, 1--3 y ago4589 (171)1.01 (.85--1.21)0.52 (.42--.63) Don\'t know/ missing1171 (59)0.81 (.56--1.16)1.09 (.50--1.04)Respiratory symptoms No26 555 (1077)1.0... Yes21 935 (610)0.69 (.62--.77)...Social gatherings None attended20 370 (872)1.0... 1--2 types of gathering attended24 719 (702)0.65 (.59--.72)... ≥3 types of gathering attended3333 (87)0.60 (.48--.75)...[^3][^4][^5][^6][^7]

Impact of Vaccination {#s3e}
---------------------

Surveys were conducted before and after vaccination with PsA-TT in 3 countries (Chad, Mali, and Niger). In Chad, where an epidemic of serogroup A meningococcal disease was occurring at the time of vaccination, a marked drop in the prevalence of genogroup A meningococcal carriage was observed 4--6 months following vaccination (from 0.7% to 0.02%; *P* \< .0001), as reported previously \[[@JIV211C17]\]. In Chad, PorA characterization of meningococcal isolates before and after vaccination showed a marked change in pattern, with a substantial reduction in the prevalence of the PorA subtype P1.20.9 associated with genogroup A (*P* \< .0001), and a marked increase in both the proportion and overall prevalence of the *cnl*-associated subtype P1.18,42-1 (Figure [5](#JIV211F5){ref-type="fig"}). However, similar rapid changes in strain prevalence over time occurred in other countries where vaccination was not introduced during the period of the surveys, including Ethiopia and Senegal. In Mali and Niger, no genogroup A meningococcal carriers were identified during the survey conducted 4--6 months before vaccination with PsA-TT, so the impact of vaccination on genogroup A carriage could not be assessed.

DISCUSSION {#s4}
==========

Results from 20 standardized surveys conducted by the MenAfriCar consortium in 7 countries across the African meningitis belt at approximately the same time confirm the findings of previous studies undertaken at single sites, at different times of the year, and with different techniques that meningococcal carriage in the African meningitis belt is both complex and highly dynamic, both in terms of the prevalence of carriage and meningococcal genogroup \[[@JIV211C5], [@JIV211C18]\]. This is illustrated well by the findings from Senegal, where carriage prevalence increased from around 3% in the first and second surveys to 19.8% in the third survey with the emergence of a strain type not observed in the previous surveys.

The overall prevalence of meningococcal carriage (3.4%) detected during the 20 surveys was substantially lower than that recorded in most population surveys undertaken in high-income countries with a temperate climate, where carriage prevalences 2 or 3 times greater are usually recorded \[[@JIV211C19]\]. Similar findings to ours were obtained recently in Burkina Faso, where surveys conducted before and after the introduction of PsA-TT showed the overall meningococcal carriage rate to be low (4% in prevaccine studies and 7% in postvaccine studies) \[[@JIV211C14]\]. In addition to the low prevalence of carriage found during the MenAfriCar surveys, the diversity of strain types was more restricted in the central part of the meningitis belt than would be expected in high-income countries with a temperate climate. The distribution of strain types in Butajira, Ethiopia, which does not have a climate typical of the Sahel, was more diverse and closer to that found in countries with a temperate climate than in countries at the center of the meningitis belt. Detection of a low prevalence of carriage and low strain diversity in countries of the meningitis belt seems, at first, to be counterintuitive but is consistent with the general theory that infectious diseases epidemics occur in situations where an infection is uncommon and population susceptibility is high.

The proportion of nongroupable, capsule-null *N. meningitidis* found in nearly all surveys was higher than that found in comparable studies conducted in high-income countries with a temperate climate \[[@JIV211C20], [@JIV211C21]\]. The reason and significance of this phenomenon is uncertain, but it warrants further investigation because the presence of these strains could influence infections with capsulated meningococci.

The prevalence of meningococcal carriage by age was consistent with most previous surveys conducted in Africa, with the highest value detected in individuals aged 5--14 years \[[@JIV211C5]\]. This age pattern is compatible with substantial transmission occurring outside households between school-aged children. Risk factors for carriage were similar to those reported previously in Africa \[[@JIV211C22]\] but different from those seen in other settings where carriage peaks in young adults \[[@JIV211C19]\]. Carriage was more prevalent in males than females, perhaps because of more-frequent social mixing among young adult males than females in Muslim societies; in rural areas than urban areas; and in those exposed to smoke, either from cigarettes or from cooking. Development of less polluting methods of cooking is a priority for many parts of the developing world \[[@JIV211C23]\] and could contribute to a reduction in the incidence of meningococcal infection, as well as the incidence of pneumonia. The absence of an association between carriage and recent respiratory symptoms contrasts with findings from studies in Burkina Faso \[[@JIV211C6]\]. The lack of any association with attendance at social gatherings was inconsistent with findings from the United Kingdom, where social behavior was closely linked to the risk of carriage \[[@JIV211C4]\]. However, in the present study, information on the number and types of gatherings attended but not the frequency of attendance was collected. Previous vaccination (within 3 years) was associated with a lower risk of carriage of capsulated meningococci. Since this finding relates mainly to the use of polysaccharide vaccines in Ghana (A+C polysaccharide vaccine) and Senegal (A+C+W polysaccharide vaccine) rather than the use of MenAfriVac, and because polysaccharide vaccines have little effect on carriage \[[@JIV211C24]\], this association is most likely due to unmeasured confounding. The odds of carriage with meningococci that possessed a capsular gene was higher in the dry season than in the rainy season, whereas there was no significant difference in the odds of carriage for unencapsulated (*cnl*) strains by season. An indoor kitchen was an additional risk factor for genogroupable meningococci, compared with capsule-null strains. These findings are consistent with the idea that the capsule protects meningococci against desiccation during aerosol transmission \[[@JIV211C25]\].

The MenAfriCar surveys were timed to permit the impact of the PsA-TT vaccine to be evaluated in Chad, Mali, and Niger. However, in Mali and Niger, carriers of group A meningococci were not found in prevaccination surveys, so it was not possible to measure the impact of vaccination on group A carriage in these countries. It seems unlikely that PsA-TT would have had any impact on other serogroups in Mali or Niger (serogroup replacement), because there were no serogroup A meningococci present prior to vaccination to displace. In Niger, where the recent epidemiology of meningococcal disease has been studied in detail \[[@JIV211C26]\], the decline in group A infections appears to have been part of a natural cycle, rather than due to vaccination. In Chad, where an epidemic of group A meningococcal disease was in progress at the time that PsA-TT was introduced in part of the country, vaccination was associated with a dramatic reduction in the prevalence of carriage of genogroup A meningococci in both vaccinated and unvaccinated participants, as reported previously \[[@JIV211C17]\] and as observed also in Burkina Faso \[[@JIV211C14]\]. However, because only data before and after vaccine introduction were obtained in both studies, and because rapid changes in carriage may occur independently of vaccination, these findings need to be considered with caution. Assessment of carriage dynamics beyond 1 year is needed to evaluate the long-term impact of PsA-TT in the meningitis belt.

An important part of the MenAfriCar project was capacity building through strengthening the ability of our study centers to undertake meningococcal carriage surveys and disease surveillance. Standardization of methods was undertaken through workshops and site visits. The Institut Pasteur (Paris, France) conducted quality-control studies for the consortium. Nevertheless, it is still possible that some of the variability in prevalence of carriage seen between centers and surveys was due to technical differences rather than to biological factors, but use of confirmatory molecular characterization of DNA samples has reduced this risk.

It is likely that widespread deployment of PsA-TT, now given to \>217 million people in countries of the meningitis belt, will prevent future epidemics of serogroup A meningococcal meningitis, at least for a number of years. However, meningococci of other serogroups (C, W, and X) have the potential to cause epidemics \[[@JIV211C27]\], and it is uncertain what impact elimination of serogroup A meningococci will have on the frequency of outbreaks caused by these serogroups. Whether or not mass vaccination drives serogroup replacement is likely to be determined in part by the complex interactions within the bacterial ecology of the pharynx, a subject that deserves further study.
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[^1]: Members of The MenAfriCar consortium and authors of this article are listed at the end of the text.

[^2]: ^a^ Data are from a postvaccination survey.

[^3]: The final multivariable logistic regression model included age group, sex, country, survey, area, crowding, household smokers, recent vaccination and kitchen location.

[^4]: Abbreviations: CI, confidence interval; OR, odds ratio.

[^5]: ^a^ Data were not reported for 135 individuals.

[^6]: ^b^ Data were missing for 67 individuals.

[^7]: ^c^ Only adults were asked about their smoking habits.
